SCHEMBL6023889

SCHEMBL6023889

Cc1cc(C=CC(=O)O)ccc1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
KDM4E B2RXH2 7/20 0.51
HSD17B10 Q99714 4/20 0.51
HPGD P15428 3/20 0.51
MAPK1 P28482 2/20 0.51
ALOX15 P16050 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
GAA P10253 3/20 0.50
SNCA P37840 2/20 0.46
PKM P14618 2/20 0.46
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA3 P07451 2/20 0.46
CA4 P22748 2/20 0.46
CA6 P23280 2/20 0.46
CA5A P35218 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6023888 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHSD17B10HPGDMAPK1
SCHEMBL2390189 0.86 TTR (0.52) CA12CA1CA2CA7CA9
SCHEMBL4611183 0.85 KDM4E (0.49) ALDH1A1KDM4EHSD17B10HPGDMAPK1
SCHEMBL4611177 0.85 KDM4E (0.49) ALDH1A1KDM4EHSD17B10HPGDMAPK1
SCHEMBL6022805 0.84 AKR1C3 (0.49) ALDH1A1KDM4EHSD17B10HPGDMAPK1
SCHEMBL6022894 0.84 KDM4E (0.48) ALDH1A1KDM4EHSD17B10HPGDMAPK1
SCHEMBL6022809 0.84 AKR1C3 (0.49) ALDH1A1KDM4EHSD17B10HPGDMAPK1
SCHEMBL6022895 0.84 KDM4E (0.48) ALDH1A1KDM4EHSD17B10HPGDMAPK1
SCHEMBL6022698 0.83 ALDH1A1 (0.46) ALDH1A1KDM4EHSD17B10HPGDMAPK1
SCHEMBL6022694 0.83 ALDH1A1 (0.46) ALDH1A1KDM4EHSD17B10HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053071-B2 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells THE BURNHAM INSTITUTE (US) 2006-05-30 US disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 EP disclosed
US-20030176506-A1 Induction of apoptosis in cancer cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-09-18 US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176506-A1 Induction of apoptosis in cancer cells MCL1, BAD, BCL2 ALDH1A1 1651/4885KDM4E 2860/4885HSD17B10 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.